4.7 Article

α-Amanitin Restrains Cancer Relapse from Drug-Tolerant Cell Subpopulations via TAF15

Journal

SCIENTIFIC REPORTS
Volume 6, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/srep25895

Keywords

-

Funding

  1. Ministry of Education, Culture, Sports, Science and Technology of Japan
  2. MEXT KAKENHI [25830121, 16K18458, 25462034, 16H01578]
  3. MIAST (Medical Innovation by Advanced Science and Technology) project of the MEXT [S1001001]
  4. Japan Prize Foundation
  5. Grants-in-Aid for Scientific Research [25830121, 16K18458, 16H01578, 16H06276, 25462034] Funding Source: KAKEN

Ask authors/readers for more resources

Cancer relapse occurs with substantial frequency even after treatment with curative intent. Here we studied drug-tolerant colonies (DTCs), which are subpopulations of cancer cells that survive in the presence of drugs. Proteomic characterization of DTCs identified stemness- and epithelial-dominant subpopulations, but functional screening suggested that DTC formation was regulated at the transcriptional level independent from protein expression patterns. We consistently found that alpha-amanitin, an RNA polymerase II (RNAPII) inhibitor, effectively inhibited DTCs by suppressing TAF15 expression, which binds to RNA to modulate transcription and RNA processing. Sequential administration of alpha-amanitin and cisplatin extended overall survival in a cancer-relapse mouse model, namely peritonitis carcinomatosa. Therefore, post-treatment cancer relapse may occur through non-distinct subpopulations and may be effectively prevented by alpha-amanitin to disrupt transcriptional machinery, including TAF15.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available